文献速递呼吸衰竭与机械通气心脑血管急症重症综合管理与镇静镇痛

中危肺栓塞的系统性溶栓、导管导向溶栓与抗凝治疗:模拟模型分析

Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-risk Pulmonary Embolism: A Simulation Modeling Analysis.
PubMed 文献 · Acad Emerg Med · 2017-09-13
一句话结论模拟模型显示,对符合条件的中危肺栓塞患者,导管导向溶栓(CDT)获得的质量调整生命年(QALYs)最多,但绝对差异小且费用高。

该研究采用个体水平状态转换模型,模拟65岁中危(次大面积)肺栓塞患者分别接受静脉tPA、导管导向溶栓(CDT)或单纯抗凝治疗的长期结局,模型输入来自随机对照试验、纵向研究及麻省总医院肺栓塞反应团队初步数据,主要终点为QALYs。结果显示CDT组平均QALYs为7.388(95%CI 7.381-7.396),高于单纯抗凝组的7.352(7.345-7.360)和静脉tPA组的7.343(7.336-7.351);CDT组出血性卒中风险高于单纯抗凝,但单纯抗凝组复发性肺栓塞不良结局更多。概率敏感性分析中CDT在98.4%的运行中为最有效策略,系统性溶栓优于单纯抗凝的时间占34.4%;CDT相较抗凝的增量成本效果比为每获得1个QALY花费317,042美元。作者认为,对符合条件者CDT获得的QALYs最多,但费用较高且绝对差异小。

要点

  • 模拟模型中,中危肺栓塞患者CDT组平均QALYs为7.388(95%CI 7.381-7.396),高于单纯抗凝组7.352(7.345-7.360)和静脉tPA组7.343(7.336-7.351)。
  • CDT组出血性卒中风险高于单纯抗凝组,但单纯抗凝组复发性肺栓塞相关不良结局更常见。
  • 概率敏感性分析显示CDT在98.4%的运行中为最有效策略,系统性溶栓优于单纯抗凝的时间占34.4%。
  • CDT相较单纯抗凝的增量成本效果比为每获得1个QALY花费317,042美元。
  • 作者认为,对符合条件的中危肺栓塞患者CDT获得的QALYs最多,但费用较高且与单纯抗凝的绝对QALY差异小。

适用人群与场景

  • 模拟的假设中危(次大面积)肺栓塞患者队列,基线病例为65岁患者。

研究设计与关键结果

  • 个体水平状态转换模型,模拟假设中危肺栓塞患者队列分别接受静脉tPA、CDT或单纯抗凝治疗的长期结局。
  • CDT组平均QALYs为7.388(95%CI 7.381-7.396),单纯抗凝组为7.352(7.345-7.360),静脉tPA组为7.343(7.336-7.351)。
  • CDT组出血性卒中风险高于单纯抗凝组;单纯抗凝组复发性肺栓塞相关不良结局更常见。
  • 敏感性分析中改变年龄和性别后结果稳定。
  • 概率敏感性分析中CDT在98.4%的运行中为最有效策略,系统性溶栓优于单纯抗凝的时间占34.4%。
  • CDT相较单纯抗凝的增量成本效果比为每获得1个QALY花费317,042美元。

证据类型、等级与局限

  • 证据类型:基于随机对照试验和纵向研究数据的决策模拟模型分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对符合条件的中危肺栓塞患者,CDT获得的QALYs最多,但费用较高且与单纯抗凝的绝对QALY差异小。
  • 作者认为,未来提供肺栓塞治疗患者纵向生活质量结局和CDT特征的研究,将有助于扩充模型输入、完善假设并验证结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Decision making around the use of thrombolysis for patients with intermediate-risk (submassive) pulmonary embolism (PE) remains challenging. Studies indicate favorable clinical outcomes with systemic thrombolytics (intravenous tissue plasminogen activator [IV tPA]), but the risk of major bleeding and hemorrhagic stroke is a deterrent. Catheter-directed thrombolysis (CDT) may be a preferable strategy, as it has been shown to have a lower risk of bleeding than systemic thrombolysis. However, a three-arm randomized control study comparing IV tPA, CDT, and anticoagulation alone, with long-term follow up, would be costly and is unlikely to be performed. The aim of this study was to use decision modeling to quantitatively estimate the differences between the three strategies.

METHODS: We created an individual-level state-transition model to simulate long-term outcomes of a hypothetical patient cohort treated with IV tPA, CDT, or anticoagulation alone. Our model incorporated clinical randomized controlled trial and longitudinal study data to inform patient characteristics and outcomes specific to each study arm. The base case was a 65-year-old patient. Additionally, we utilized preliminary data published by the Pulmonary Embolism Response Team at the Massachusetts General Hospital. Variance in model inputs was addressed with deterministic and probabilistic sensitivity analyses. Our primary endpoint was quality-adjusted life-years (QALYs). Secondary endpoints included total cost and incremental cost-effectiveness ratios (ICERs).

RESULTS: Catheter-directed thrombolysis (mean, 95% confidence interval [CI] = 7.388 [7.381-7.396] QALYs) resulted in the most long-term utility for eligible patients compared to anticoagulation alone (7.352 [7.345-7.360] QALYs) or IV tPA (7.343 [7.336-7.351] QALYs). Patients receiving CDT had an elevated risk of hemorrhagic stroke in comparison to anticoagulation alone; however, patients treated with anticoagulation alone were more likely to experience recurrent PE associated adverse outcomes. Results were stable with sensitivity analyses varying age and sex. Our probabilistic sensitivity analysis assessing joint variance predicts CDT to be the most effective strategy, when measured by mean QALYs, in 98.4% of runs, while systemic thrombolysis was favored over anticoagulation alone 34.4% of the time. The ICER of CDT compared to anticoagulation was $317,042 per QALY gained.

CONCLUSION: In our model, for those eligible, CDT results in the largest number of QALYs for patients with intermediate-risk PE, although it is relatively expensive and the absolute difference in QALYs between anticoagulation alone and CDT is small. Future studies that provide data on longitudinal quality-of-life outcomes of patients treated for PE and characteristics of CDT would be beneficial to augment model inputs, inform assumptions, and validate results.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Kabrhel C, Ali A, Choi JG, et al. Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-risk Pulmonary Embolism: A Simulation Modeling Analysis. Acad Emerg Med. 2017. PMID: 28650086. doi:10.1111/acem.13242

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。